Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation approach aims to tame sarcoma with fewer sessions

NCT ID NCT03972930

Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a shorter course of high-dose radiation (hypofractionated radiotherapy) for soft tissue sarcoma. The goal is to see if this approach can control the tumor for at least two years while reducing damage to nearby healthy tissue. About 48 adults with inoperable or metastatic sarcoma will receive the treatment and be followed for up to five years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hypofractionated radiotherapy (high-dose radiation given in fewer sessions)
What this could lead to
If successful, this could offer a more convenient and potentially safer radiation option for people with soft tissue sarcoma, improving local tumor control.
What could go wrong
This is a small, early-phase trial (48 participants) with no control group, so results may not apply broadly. The approach may still cause side effects or fail to control the tumor long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

48 people

The number who actually took part.

Started

Jun 2019

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biopsy proven soft tissue sarcoma, either localized and inoperable/unresectable or metastatic, that is deemed by the treating physician to be targetable with hypofractionated radiotherapy. * Participant refuses surgery or is aware that surgery is not recommended for them * Karnofsky performance status \> 60 * Able to understand and sign an informed consent form Exclusion Criteria: * Pregnant * Chemotherapy or systemic anti-cancer treatment within the preceding two weeks * Unable to undergo imaging or positioning necessary for radiotherapy planning * Prior radiation therapy in the field that, at the discretion of the treating physician, prevents safe delivery of hypofractionated radiotherapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Soft tissue sarcoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Soft tissue sarcoma

Contacts and locations

Locations

  • University of Wisconsin

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.